Choices About Genetic Testing And Learning Your Risk with Smart Technology (CATALYST)
The study's objectives are to: 1) finalize the development and optimize usability of the CATALYST digital intervention (i.e., RA also known as relational assistant (RA)); 2) evaluate the feasibility and acceptability of a streamlined cancer genomic care delivery in cancer survivors. Participants will be randomized to one of two study arms which are the RA intervention vs. enhanced usual care (EUC); and 3) Conduct a process evaluation to measure barriers/facilitators to GC, GT and use of the CATALYST intervention and engagement with the RA.
Other Female Genital
Prostate
Colon
Ovary
Breast
- Rutgers Cancer Institute of New Jersey
Inclusion Criteria
- User/Usability Testing
1. Age 18 or older
2. Diagnosed with ovarian, fallopian tube, peritoneal, breast, pancreatic,
colorectal, endometrial or prostate cancer
3. Speak/read and understand English
4. Capable of providing informed consent
5. Have Internet access (via smartphone, tablet, or computer)
- Feasibility Randomized Trial
1. Age 18 or older
2. Diagnosed with epithelial ovarian cancer, fallopian tube cancer, primary
peritoneal cancer, colorectal cancer, breast cancer at age 50 or below or triple
negative breast cancer at age 60 or below, pancreatic cancer, or endometrial
cancer at age 50 or below, regional/metastatic/intraductal prostate cancer or
prostate cancer with a Gleason score ≥7 per NCCN guidelines
3. Speak/read and understand English
4. Capable of providing informed consent
5. Have Internet access (via smartphone, tablet or computer)
6. Have not previously undergone GT for hereditary cancer predisposition
Exclusion Criteria
- Participants will be 18 years of age or older because germline genetic testing is
generally not recommended in children when the test results would not impact clinical
management. Participants from the user and usability testing phases are not eligible
to participate in the feasibility trial.
Please note that we have obtained the inclusion and exclusion criteria information from the National Institutes of Health’s clinical trials web site ClinicalTrials.gov. The listed criteria may not necessarily reflect recent amendments to the protocol and the current criteria.
For further information about clinical trials, please contact us at 732-235-7356.